Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
GRFS — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

2.09

Margin Of Safety %

41

Put/Call OI Ratio

0.38

EPS Next Q Diff

EPS Last/This Y

0.48

EPS This/Next Y

0.29

Price

7.79

Target Price

14.43

Analyst Recom

2

Performance Q

-11.03

Upside

N/A

Beta

0.67

Ticker: GRFS




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-15GRFS8.70.370.502705
2026-04-20GRFS8.470.310.642552
2026-04-23GRFS7.990.334.052602
2026-04-24GRFS8.090.370.072712
2026-04-27GRFS8.120.370.672734
2026-04-28GRFS8.070.370.002742
2026-04-29GRFS7.910.3510.002836
2026-04-30GRFS8.220.3510.002836
2026-05-01GRFS8.230.3510.002836
2026-05-04GRFS8.230.371.582866
2026-05-05GRFS8.270.39999.992916
2026-05-06GRFS8.410.3977.002917
2026-05-07GRFS8.060.423.172978
2026-05-08GRFS8.090.450.103029
2026-05-11GRFS7.80.420.172982
2026-05-12GRFS7.550.420.132982
2026-05-13GRFS7.70.380.173416
2026-05-14GRFS7.80.380.063410
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-15GRFS8.70- - 1.17
2026-04-16GRFS8.60- - 1.17
2026-04-17GRFS8.73- - 1.17
2026-04-20GRFS8.48- - 1.17
2026-04-21GRFS8.38- - 1.17
2026-04-22GRFS8.38- - 1.17
2026-04-23GRFS7.99- - 1.17
2026-04-24GRFS8.09- - 1.17
2026-04-27GRFS8.13- - 1.17
2026-04-28GRFS8.08- - 1.17
2026-04-30GRFS8.23- - 1.17
2026-05-01GRFS8.23- - 1.17
2026-05-04GRFS8.23- - 1.17
2026-05-05GRFS8.28- - 1.17
2026-05-06GRFS8.40- - 1.17
2026-05-07GRFS8.06- - 1.17
2026-05-08GRFS8.08- - 1.17
2026-05-11GRFS7.80- - 1.17
2026-05-12GRFS7.5523.9- 1.17
2026-05-13GRFS7.6923.9- 1.17
2026-05-14GRFS7.7923.9- 1.17
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




13 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-04-15GRFS0-1.202.04
2026-04-16GRFS0-1.202.04
2026-04-17GRFS0-1.202.04
2026-04-20GRFS0-1.422.04
2026-04-21GRFS0-1.422.04
2026-04-22GRFS0-1.422.04
2026-04-23GRFS0-1.422.04
2026-04-24GRFS0.00-1.422.04
2026-04-27GRFS0.00-1.312.09
2026-04-28GRFS0.00-1.312.09
2026-04-29GRFS0.00-1.312.09
2026-04-30GRFS0.00-1.312.09
2026-05-01GRFS0.00-1.312.09
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
13 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.29

Avg. EPS Est. Next Quarter

0.27

Insider Transactions

Institutional Transactions

-1.31

Beta

0.67

Average Sales Estimate Current Quarter

1951

Average Sales Estimate Next Quarter

1971

Fair Value

10.98

Quality Score

61

Growth Score

89

Sentiment Score

7

Actual DrawDown %

59.2

Max Drawdown 5-Year %

-70.7

Target Price

14.43

P/E

12.21

Forward P/E

6.24

PEG

0.28

P/S

0.25

P/B

0.9

P/Free Cash Flow

2.4

EPS

0.67

Average EPS Est. Cur. Y​

1.17

EPS Next Y. (Est.)

1.46

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

5.39

Relative Volume

0.19

Return on Equity vs Sector %

-19.3

Return on Equity vs Industry %

-29.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Grifols, S.A.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 25000
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
GRFS

Latest News

Caricamento notizie per GRFS
stock quote shares GRFS – Grifols, S.A. Stock Price stock today
news today GRFS – Grifols, S.A. stock forecast ,stock prediction 2023 2024 2025
marketwatch GRFS – Grifols, S.A. yahoo finance google finance
stock history GRFS – Grifols, S.A. invest stock market
stock prices GRFS premarket after hours
ticker GRFS fair value insiders trading